What is Kiniksa Pharmaceuticals International, plc's Shariah compliance score?

Kiniksa Pharmaceuticals International, plc (KNSA) has a Shariah compliance score of 85/100 (Grade: A, Very Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Kiniksa Pharmaceuticals International, plc pass AAOIFI screening?

Kiniksa Pharmaceuticals International, plc (KNSA) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (KNSA: 0.2%), (3) interest-bearing deposits below 30% (KNSA: 8.7%), and (4) prohibited income below 5% (KNSA: 1.5%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Kiniksa Pharmaceuticals International, plc stock?

Kiniksa Pharmaceuticals International, plc (KNSA) has a non-permissible income ratio of 1.46%. Muslim investors should purify this percentage of any dividends received and capital gains realized from KNSA shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Kiniksa Pharmaceuticals International, plc for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Kiniksa Pharmaceuticals International, plc (KNSA) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about KNSA's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

KNSA: Is Kiniksa Pharmaceuticals International, plc Halal?

Kiniksa Pharmaceuticals International, plc

NASDAQHealthcareGB

$63.44

-2.97%

Market Cap: 4.8B

Compliance Status

Halal

Screened on Jul 19, 2026 · AAOIFI Standard 21

Very Good

85Score

Is Kiniksa Pharmaceuticals International, plc (KNSA) halal? Halal. Based on AAOIFI screening, Kiniksa Pharmaceuticals International, plc passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 85/100 (Grade: A).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.2% of 30.0% limit

What this means for you

You can own KNSA

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 1.5% of your income from KNSA

That is about $1.50 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Sector: Healthcare · Industry: Medical - Pharmaceuticals

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 19, 2026

Compliance History

Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track KNSA and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Kiniksa Pharmaceuticals International, plc (KNSA) halal to invest in?

Based on AAOIFI Standard 21 screening, Kiniksa Pharmaceuticals International, plc (KNSA) is rated Halal with a compliance grade of A (Very Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Kiniksa Pharmaceuticals International, plc get a A compliance rating?

Kiniksa Pharmaceuticals International, plc (KNSA) received a grade of A (Very Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.2% (limit 30%); interest-bearing deposits of 8.7% (limit 30%); prohibited income of 1.46% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Kiniksa Pharmaceuticals International, plc's Shariah verdict?

Kiniksa Pharmaceuticals International, plc's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Kiniksa Pharmaceuticals International, plc re-screened for Shariah compliance?

Kiniksa Pharmaceuticals International, plc (KNSA) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 19, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.